Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
SUIC Sino United Worldwide Consolidated Ltd
PSRU Valiant Eagle Inc
ON ON Semiconductor Corp
KHC Kraft Heinz Co
SUMO Sumo Logic Inc
TPGY+ TPG Pace Beneficial Finance Corp. *W EXP 10/09/2027
CSTA^ Constellation Acquisition Corp I
HFBL Home Federal Bancorp Inc of Louisiana
FSEA First Seacoast Bancorp
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Closing Price
$115.42
Day's Change
-0.82 (-0.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
116.36
Day's Low
114.87
Volume
(Light)
Volume:
4,471,372

10-day average volume:
7,508,794
4,471,372

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces That a Class Action Lawsuit Has Been Filed Against Clover Health Investments, Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

12:32 pm ET April 5, 2021 (Accesswire) Print

LOS ANGELES, CA / ACCESSWIRE / April 5, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Clover Health Investments, Corp. f/k/a Social Capital Hedosophia Holdings Corp. III ("Clover" or "the Company") (NASDAQ:CLOV)(NASDAQ:CLOVW) violations of the federal securities laws.

Image: https://www.accesswire.com/users/newswire/images/638988/f3ad0134ac2b059c9fd19724e14706c9.jpg

Investors who purchased or otherwise acquired publicly traded Clover securities between October 6, 2020 and February 4, 2021, inclusive (the "Class Period"); and/or purchased or otherwise acquired Clover securities pursuant or traceable to the registration statement and prospectus issued in connection with the December 2020 Merger of Clover and Social Capital III, are encouraged to contact the firm before April 6, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Clover was the subject of an active DOJ investigation of at least 12 issues including kickbacks and deceptive marketing. The investigation represented a major threat to the Company's future due to its dependence on Medicare for revenue. The Company's sales were not driven by its "best-in-class" technology as it touted, but rather by misleading marketing practices aimed at senior citizens. A considerable portion of the Company's sales were derived from an undisclosed relationship with a brokerage firm controlled by the Clover's head of sales. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Clover, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

SOURCE: The Schall Law Firm

View source version on accesswire.com:

https://www.accesswire.com/638988/FINAL-DEADLINE-TOMORROW-The-Schall-Law-Firm-Announces-That-a-Class-Action-Lawsuit-Has-Been-Filed-Against-Clover-Health-Investments-Corp-and-Encourages-Investors-with-Losses-in-Excess-of-100000-to-Contact-the-Firm

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.